InflaRx N.V. (IFRX)
IFRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1708688/000121390026032065/0001213900-26-032065-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2025-12-31. Converted from EUR at 0.8933 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | IFRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Germany |
| IPO year | 2017 |
| SEC CIK | 0001708688 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | P7 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $33K |
| Net income | -$51.1M |
| Operating income | Not in SEC XBRL data |
| Net margin | -155582.1% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6956.4× |
Reported in EUR; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document 425B5 | 424B5 | 2026-08-14 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-03-20 |
| Latest quarterly / interim | 6-K | 2026-08-06 |
Source: SEC EDGAR submissions feed, 286 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GLSI | Greenwich LifeSciences Inc. | $15.50 | -12.77% | $227.5M |
| ZNTL | Zentalis Pharmaceuticals Inc. | $2.40 | -4.76% | $227.2M |
| IMRX | Immuneering Corporation | $3.56 | -7.77% | $230.3M |
| NATR | Nature's Sunshine Products Inc. | $12.76 | +0.39% | $224.5M |
| LRMR | Larimar Therapeutics Inc. | $2.16 | -14.63% | $224.4M |
| SLGL | Sol-Gel Technologies Ltd. | $68.30 | -5.66% | $223.6M |
| KROS | Keros Therapeutics Inc. | $11.23 | -3.27% | $222.7M |
| SIGA | SIGA Technologies Inc. | $3.08 | -2.53% | $221.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier